Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Ipilimumab (Yervoy®) is recommended as an option for use within NHS Wales as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age to < 18 years of age. This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | ipilimumab (Yervoy®) | ||
| Formulation | 5 mg/ml concentrate for solution for infusion | ||
| Reference number | 3604 | ||
| Indication | Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age to < 18 years of age. |
||
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd | ||
| BNF chapter | Malignant disease & immunosuppression | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 1818 | ||
| NMG meeting date | 05/09/2018 | ||
| AWMSG meeting date | 17/10/2018 | ||
| Date of issue | 02/11/2018 | ||
| Date of last review | April 2022 | ||
| Commercial arrangement | PAS | ||
| Further information Ipilimumab has previously been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of previously untreated (TA319) and treated (TA268) advanced (unresectable or metastatic) melanoma in adults, and is available in NHS Wales for adults under a Department of Health Patient Access Scheme (PAS). This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||